ClinicalTrials.gg
CompletedNCT03909074Updated May 26, 2022

Clinical Trial of Enterovirus 71(EV71) Inactivated Vaccine in Children Aged 36-71 Months

A Phase 3 interventional study of 36-71 months old children-experimental EV71 vaccine. and 36-71 months old children-control EV71 vaccine. in Hand, Foot and Mouth Disease, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 6 Months to 71 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by Sinovac Biotech Co., Ltd · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
6 Months to 71 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd — 4 open to participants now, 4 under way, 2 of them phase 3. Hand, Foot and Mouth Disease · Sinovac Biotech Co., Ltd.

Enrollment
6th of 15
900 · median 744
Started
2019
with 2 others
Phase 3
5 of 20
2 open now
Registered
9th of 20
by date

Among the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, this one is the 6th largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2019, is one of 5 in phase 3, and was the 9th registered.

Hand, Foot and Mouth Disease

59 studies on the registry are indexed under Hand, Foot and Mouth Disease; 10 are open to participants now.

Browse Hand, Foot and Mouth Disease studies →

Open to participants now

4 of the 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 4 Hand, Foot and Mouth Disease studies recruiting now, 1 sets no upper age limit and 3 stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 6 Months to 71 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Hand, Foot and Mouth Disease by Sinovac Biotech Co., Ltd, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, to evaluate the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd, and the control vaccine was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.

Read the detailed description

This study is a randomized, double-blind, single-center, controlled phase III clinical trial in children aged 36-71 months, and bridging trial between agegroup of 6-35 and 36-71 months. The purpose of this study is to evaluate the immunogenicity and safety of the experimental EV71 vaccine in children aged 36-71 months. The primary objective of this study is to evaluate the non-inferiority of experimental EV71 vaccine compared to the control EV71 vaccine in children aged 36-71 months, and the non-inferiority of EV71 vaccine used in children aged 36-71 months compared to 6-35 months. The secondary objective is to evaluate the safety of the experimental vaccine used in children aged 36-71 months. The experimental vaccine is manufactured by Sinovac Biotech Co., Ltd, and the control vaccine is manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences. 600 children aged 36-71 months will be randomly assigned in to receive the experimental vaccine or control vaccine, and 300 children aged 6-35 months will receive the experimental vaccine.

03

Conditions studied

  • Hand, Foot and Mouth Disease
04

Who can participate

Ages eligible
6 Months to 71 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers ≥ 2 years old;
  • Proven legal identity;
  • Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment.

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with EV71 vaccine;
  • History of hand, foot and mouth disease;
  • History of allergy to any vaccine or vaccine ingredient, asthma, serious adverse reactions to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;
  • Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;
  • disease or immunodeficiency/;
  • Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;
  • History of thyroidectomy, no spleen and functional spleen;
  • Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or abnormalities) , or obvious bruising or coagulation disorders;
  • Receipt of any of the following products:

    1. Any immunosuppressant, cytotoxic medicine, or inhaled (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry
    2. Blood products within 2 months prior to study entry
    3. Any other products (drug or vaccine)within 30 days prior to study entry
    4. Any within 14 days prior to study entry
    5. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;
  • Acute disease or acute stage of chronic disease within 7 days prior to study entry;
  • Axillary temperature > 37.0 °C;
  • Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
900 participants (actual)

Study arms

  • Experimental
    Experimental group

    36-71 months old children-experimental EV71 vaccine.

    Biological: 36-71 months old children-experimental EV71 vaccine.

  • Active comparator
    Vaccine-controlled group

    36-71 months old children-control EV71 vaccine.

    Biological: 36-71 months old children-control EV71 vaccine.

  • Active comparator
    Age-controlled group

    6-35 months old children-experimental EV71 vaccine.

    Biological: 6-35 months old children-experimental EV71 vaccine.

Interventions

  • Biological36-71 months old children-experimental EV71 vaccine.

    Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

  • Biological36-71 months old children-control EV71 vaccine.

    Two doses control EV71 vaccine at the 0, 30 days vaccination schedule.

  • Biological6-35 months old children-experimental EV71 vaccine.

    Two doses experimental EV71 vaccine at the 0, 30 days vaccination schedule.

06

What researchers measure

Primary outcomes

  1. The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:8

    Subjects whose pre-immune antibody titer \< 1:8 and post-immune antibody titer ≥ 1:8, or those whose pre-immune antibody titer ≥ 1:8 and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted.

    Time frame: 30 days after two doses

  2. The Geometric mean titer (GMT) of the EV71 neutralizing antibody in the susceptible population

    The susceptible population refer to the subjects whose pre-immune antibody titer \<1:8

    Time frame: 30 days after two doses

Secondary outcomes

  1. The overall incidence of adverse reactions

    After each dose, a 30-minute safety observation will be conducted immediately. The body temperature, solicited local and general adverse events (AE) on day 0-7 were reported. The solicited local symptoms include pain, induration, redness, swelling, rash, and pruritus. The solicited general adverse symptoms include allergy, fatigue, irritability, inappetence, vomiting, diarrhea, and fever. Unsolicited adverse events on day 0-30 were also reported, which include the unsolicited symptoms happened within 0-7 days, and any symptoms happened within the 8-28 days. Each AE case will be reviewed by the investigator to determine whether it was an adverse reaction (The vaccination-related AE). The incidence of adverse reactions=Number of subjects who have adverse reactions of any symptoms/number of all the subjects whose safety information are collected.

    Time frame: 0-30 days after each dose

  2. The incidence of the serious adverse events (SAE)

    After each dose, the serious adverse events in the safety observation period will be reported. The SAE incidence=Number of subjects who have SAE of any symptoms/Number of subjects whose safety information are collected.

    Time frame: 0-30 days after each dose

  3. The seroconversion rates (SCR) of the EV71 neutralizing antibody calculated based on the cutoff value of 1:16, 1:32, and 1:64 respectively

    Subjects whose pre-immune antibody titer \<1:16(1:32/1:64) and post-immune antibody titer ≥1:16(1:32/1:64), or those whose pre-immune antibody titer ≥ 1:16(1:32/1:64) and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted.

    Time frame: 30 days after two doses

  4. The Geometric mean titer (GMT) of the EV71 neutralizing antibody

    The GMT 30 days after two doses.

    Time frame: 30 days after two doses

07

Study locations

1 site
  • Yun County Center for Disease Control and Prevention
    Lincang, Yunnan 675800, China
08

References and documents

Publications

  • Zhang L, Gao F, Zeng G, Yang H, Zhu T, Yang S, Meng X, Mao Q, Liu X. Immunogenicity and Safety of Inactivated Enterovirus 71 Vaccine in Children Aged 36-71 Months: A Double-Blind, Randomized, Controlled, Non-inferiority Phase III Trial. J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):440-447. doi: 10.1093/jpids/piaa129. PubMed 33269798 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jun 2019, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 9, 2019
StartActual
Mar 10, 2019
Primary completionActual
Jun 17, 2019
CompletionActual
Nov 13, 2019
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03909074
Responsible party
Sponsor
First posted
Apr 9, 2019
Start date
Mar 10, 2019
Primary completion
Jun 17, 2019
Completion
Nov 13, 2019
Last update
May 26, 2022

Study contacts

Lifen Zhang, Master
principal investigator · Yunnan Center for Disease Control and Prevention

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion